Publications by authors named "Laura Di Rito"
Article Synopsis
- Multiple myeloma (MM) is a serious illness where certain blood cells grow uncontrollably in the bone marrow, making it hard for patients to get better.
- Researchers found that a special type of RNA called NEAT1 helps these cancer cells grow, making it a potential target for new treatments.
- They discovered that combining NEAT1 blockage with a specific drug called AURKA inhibitors could kill these cancer cells more effectively, especially since high levels of both NEAT1 and AURKA are linked to worse health outcomes in patients.
We developed an innovative millifluidic organ-on-a-chip device, named MINERVA 2.0, that is optically accessible and suitable to serial connection. In the present work, we evaluated MINERVA 2.
View Article and Find Full Text PDFAlthough dietary fructose is associated with an elevated risk for pancreatic cancer, the underlying mechanisms remain elusive. Here, we report that ketohexokinase (KHK), the rate-limiting enzyme of fructose metabolism, is a driver of PDAC development. We demonstrate that fructose triggers KHK and induces fructolytic gene expression in mouse and human PDAC.
View Article and Find Full Text PDFBackground And Purpose: Endoplasmic reticulum (ER) stress triggers an adaptive response in tumours which fosters cell survival and resilience to stress. Activation of the ER stress response, through its PERK branch, promotes phosphorylation of the α-subunit of the translation initiation factor eIF2, thereby repressing general protein translation and augmenting the translation of ATF4 with the downstream CHOP transcription factor and the protein disulfide oxidase, ERO1-alpha EXPERIMENTAL APPROACH: Here, we show that ISRIB, a small molecule that inhibits the action of phosphorylated eIF2alpha, activating protein translation, synergistically interacts with the genetic deficiency of protein disulfide oxidase ERO1-alpha, enfeebling breast tumour growth and spread.
Key Results: ISRIB represses the CHOP signal, but does not inhibit ERO1.
Article Synopsis
- Comprehensive genomic studies identify key mutations in cancer progression, but the related transcriptional changes are often unclear due to analysis biases.
- A new comprehensive prostate cancer transcriptome atlas has been created, offering insights into the qualitative and quantitative aspects of tumor progression, revealing that most cancers follow a similar trajectory marked by specific biological changes.
- Using advanced models and single-cell analysis, researchers show that tumor progression is driven by transcriptional adaptation rather than existing cancer cell populations, with EZH2 identified as a crucial gene influencing this process; a web resource is available for further exploration of these transcriptional changes.